{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-061148","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-05-14T20:06:05+00:00","discovered_at":"2026-05-14T20:08:00.231672+00:00","generated_at":"2026-05-14T21:01:20.962367+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MetaVia Q1 net loss $3.8M; Phase 1 Part 3 dosing started for DA-1726","bullets":["Net loss of $3.8M ($0.79 per share) vs $3.7M ($3.93 per share) in Q1 2025.","Cash and cash equivalents $13.7M as of March 31, 2026, sufficient into Q4 2026.","First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726; data expected Q4 2026.","January 2026 public offering raised ~$9.3M gross proceeds to fund operations.","R&D expenses $2.1M, G&A $1.9M; total operating expenses $4.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-061148","json":"https://secwatch.observer/filing/0001104659-26-061148.json","markdown":"https://secwatch.observer/filing/0001104659-26-061148.md","text":"https://secwatch.observer/filing/0001104659-26-061148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/0001104659-26-061148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/mtva-20260514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:01:20.962367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ffe0b7a24452a54c0aa3d288750770376f3f9ac1","claim":"MetaVia Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"issued a press release announcing its financial results for the first quarter ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/0001104659-26-061148-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}